New deal launched to boost Qld's clinical trials industry
Queensland is breaking into one of the world's major markets for clinical trials of medical and pharmaceutical products and equipment.
"Queensland is creating a strong reputation for quality and accuracy for medical and pharmaceutical goods in Japan," Robertson said.
"This Memorandum of Understanding is a milestone in QCTN's continued push into overseas markets to attract clinical and preclinical trials to Queensland.
"The new agreement will open the door for QCTN members to become the first choice for Kurume researchers. This means Queensland companies will now have a better chance to secure contracts to undertake the medical research and trials required to develop new therapeutic products being created by members of the Kurume Cluster.
"The Kurume Research Park Medical Cluster includes 4 medical schools, Kurume University, Kyushu University, Fukuoka University, and University of Occupational and Environmental Health Japan."
Japan is Queensland's number one export destination, receiving $16.5 billion worth of Queensland's total merchandise exports in 2008-09.
"The Bligh Government is supporting Queensland businesses to enter this important market, boosting our economy and creating jobs."
The announcement comes during the international Bio Seminar in Fukuoka.
"The Seminar brings together biotech industry representative from across Asia and other countries to enhance research, development and business networking, support and co-operation," Robertson said.
"The QCTN delegation will be able to advise companies attending the seminar on the advantages of conducting trials in Queensland and to also consider the globally recognised capabilities of Queensland as a one-stop destination for their bio-tech and product development needs.
"QCTN's growing profile and success in the Japanese market will assist in further promoting and showcasing the world class capabilities and facilities that Queensland has to offer in the biotech sector," Robertson said.